Tricks with tetramers: how to get the most from multimeric peptide–MHC

The development of fluorochrome‐conjugated peptide–major histocompatibility complex (pMHC) multimers in conjunction with continuing advances in flow cytometry has transformed the study of antigen‐specific T cells by enabling their visualization, enumeration, phenotypic characterization and isolation from ex vivo samples. Here, we bring together and discuss some of the ‘tricks’ that can be used to get the most out of pMHC multimers. These include: (1) simple procedures that can substantially enhance the staining intensity of cognate T cells with pMHC multimers; (2) the use of pMHC multimers to stain T cells with very‐low‐affinity T‐cell receptor (TCR)/pMHC interactions, such as those that typically predominate in tumour‐specific responses; and (3) the physical grading and clonotypic dissection of antigen‐specific T cells based on the affinity of their cognate TCR using mutant pMHC multimers in conjunction with new approaches to the molecular analysis of TCR gene expression. We also examine how soluble pMHC can be used to examine T‐cell activation, manipulate T‐cell responses and study allogeneic and superantigen interactions with TCRs. Finally, we discuss the problems that arise with pMHC class II (pMHCII) multimers because of the low affinity of TCR/pMHCII interactions and lack of ‘coreceptor help’.

[1]  D. Speiser,et al.  Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. , 2003, Journal of Immunology.

[2]  P. Marrack,et al.  Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. , 1998, Immunity.

[3]  Yi Li,et al.  Design of Soluble Recombinant T Cell Receptors for Antigen Targeting and T Cell Inhibition* , 2005, Journal of Biological Chemistry.

[4]  D. Tuveson,et al.  A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Sewell,et al.  High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining 1 , 2003, The Journal of Immunology.

[6]  Jay A. Berzofsky,et al.  High-Avidity CTL Exploit Two Complementary Mechanisms to Provide Better Protection Against Viral Infection Than Low-Avidity CTL , 2001, The Journal of Immunology.

[7]  Horst Vogel,et al.  CD8 kinetically promotes ligand binding to the T-cell antigen receptor. , 2005, Biophysical journal.

[8]  J. McCluskey,et al.  T-cell receptor bias and immunity. , 2008, Current opinion in immunology.

[9]  D. Speiser,et al.  α3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells1 , 2003, The Journal of Immunology.

[10]  J. E. Brewer,et al.  The HLA A*0201–restricted hTERT540–548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor , 2007, Molecular Cancer Therapeutics.

[11]  Mark M. Davis,et al.  Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. , 2003, The Journal of clinical investigation.

[12]  R. Zinkernagel,et al.  Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes , 1998, The Journal of experimental medicine.

[13]  E. Palmer,et al.  A Role for the α-Chain Connecting Peptide Motif in Mediating TCR-CD8 Cooperation , 2002, The Journal of Immunology.

[14]  J. Altman,et al.  Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.

[15]  R. Zamoyska,et al.  Co‐capping studies reveal CD8/TCR interactions after capping CD8β polypeptides and intracellular associations of CD8 with p56lck , 1998, European journal of immunology.

[16]  B. Walker,et al.  Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. , 2008, The Journal of clinical investigation.

[17]  D. Plas,et al.  Negative regulation of antigen receptor signaling in lymphocytes , 1998, Journal of Molecular Medicine.

[18]  E. Palmer,et al.  A role for the alpha-chain connecting peptide motif in mediating TCR-CD8 cooperation. , 2002, Journal of immunology.

[19]  M. Alexander-Miller,et al.  Differential expansion and survival of high and low avidity cytotoxic T cell populations during the immune response to a viral infection. , 2000, Cellular immunology.

[20]  R. Phillips,et al.  Anti‐coreceptor antibodies profoundly affect staining with peptide‐MHC class I and class II tetramers , 2006, European journal of immunology.

[21]  M. Alexander-Miller,et al.  Cutting Edge: CD8+ T Cell Clones Possess the Potential to Differentiate into both High- and Low-Avidity Effector Cells1 , 2007, The Journal of Immunology.

[22]  Andrew K. Sewell,et al.  Human TCR-Binding Affinity is Governed by MHC Class Restriction1 , 2007, The Journal of Immunology.

[23]  S. Mark,et al.  Soluble MHC-Peptide Complexes Induce Rapid Death of CD8+ CTL1 , 2005, The Journal of Immunology.

[24]  F. Wurm,et al.  CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56(lck) complexes. , 2001 .

[25]  G. Boivin,et al.  A Single-Chain Class II MHC-IgG3 Fusion Protein Inhibits Autoimmune Arthritis by Induction of Antigen-Specific Hyporesponsiveness1 , 2002, The Journal of Immunology.

[26]  H. Ploegh,et al.  Mouse MHC class I tetramers that are unable to bind to CD8 reveal the need for CD8 engagement in order to activate naive CD8 T cells , 2002, European journal of immunology.

[27]  D. Speiser,et al.  Discrepancy between ELISPOT IFN-γ secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  L. Borysiewicz,et al.  TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. , 1999, Journal of immunology.

[29]  R. Zinkernagel,et al.  Peripheral clonal deletion of antiviral memory CD8+ T cells , 1993, European journal of immunology.

[30]  M. Sadelain,et al.  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection , 2007, Nature Medicine.

[31]  D. Price,et al.  Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. , 1999, Journal of immunology.

[32]  Andrew K. Sewell,et al.  Interaction between the CD8 Coreceptor and Major Histocompatibility Complex Class I Stabilizes T Cell Receptor-Antigen Complexes at the Cell Surface* , 2005, Journal of Biological Chemistry.

[33]  D. Scheinberg,et al.  Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model. , 2006, Blood.

[34]  M. Glick,et al.  Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region , 2007, European journal of immunology.

[35]  Andrew K. Sewell,et al.  The Human CD8 Coreceptor Effects Cytotoxic T Cell Activation and Antigen Sensitivity Primarily by Mediating Complete Phosphorylation of the T Cell Receptor ζ Chain* , 2001, The Journal of Biological Chemistry.

[36]  A. Singer,et al.  Association of the Adaptor Molecule Lat with Cd4 and Cd8 Coreceptors Identifies a New Coreceptor Function in T Cell Receptor Signal Transduction , 1999, The Journal of experimental medicine.

[37]  H. Ploegh,et al.  Class I negative CD8 T cells reveal the confounding role of peptide-transfer onto CD8 T cells stimulated with soluble H2-Kb molecules , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Andrew K. Sewell,et al.  The CD8 T Cell Coreceptor Exhibits Disproportionate Biological Activity at Extremely Low Binding Affinities* , 2003, Journal of Biological Chemistry.

[39]  I. Messaoudi,et al.  Direct Link Between mhc Polymorphism, T Cell Avidity, and Diversity in Immune Defense , 2002, Science.

[40]  D. Speiser,et al.  Functional Avidity of Tumor Antigen-Specific CTL Recognition Directly Correlates with the Stability of MHC/Peptide Multimer Binding to TCR1 , 2002, The Journal of Immunology.

[41]  Richard A Koup,et al.  T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. , 2004, Immunity.

[42]  O. Michielin,et al.  CD3δ Establishes a Functional Link between the T Cell Receptor and CD8* , 2003, The Journal of Biological Chemistry.

[43]  S. Hutchinson,et al.  Anti-CD8 Antibodies Can Inhibit or Enhance Peptide-MHC Class I (pMHCI) Multimer Binding: This Is Paralleled by Their Effects on CTL Activation and Occurs in the Absence of an Interaction between pMHCI and CD8 on the Cell Surface 1 , 2003, The Journal of Immunology.

[44]  R. Phillips,et al.  Use of Peptide-Major Histocompatibility Complex Tetramer Technology To Study Interactions between Staphylococcus aureus Proteins and Human Cells , 2007, Infection and Immunity.

[45]  P. Courtoy,et al.  Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. , 2008, Immunity.

[46]  M. Alexander-Miller,et al.  Peptide Requirement for CTL Activation Reflects the Sensitivity to CD3 Engagement: Correlation with CD8αβ Versus CD8αα Expression1 , 2001, The Journal of Immunology.

[47]  Rolf M. Zinkernagel,et al.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.

[48]  C. Janeway,et al.  Physical association of CD4 with the T cell receptor. , 1992, Journal of immunology.

[49]  A. Sewell,et al.  Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers , 2009, Journal of immunological methods.

[50]  S. Davis,et al.  The structure and ligand interactions of CD2: implications for T-cell function. , 1996, Immunology today.

[51]  Aaruni Khanolkar,et al.  Maintenance, Loss, and Resurgence of T Cell Responses During Acute, Protracted, and Chronic Viral Infections1 , 2004, The Journal of Immunology.

[52]  P. Klenerman,et al.  Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining1 , 2005, The Journal of Immunology.

[53]  A. Zajac,et al.  Ablation of CD8 and CD4 T Cell Responses by High Viral Loads1 , 2003, The Journal of Immunology.

[54]  A. McMichael,et al.  The T cell repertoire in infection and vaccination: implications for control of persistent viruses. , 2007, Current opinion in immunology.

[55]  Susan M. Drake A Novel Approach. , 1996 .

[56]  R. Phillips,et al.  Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor , 2008, Nature Medicine.

[57]  M. Alexander-Miller,et al.  Dose‐dependent modulation of CD8 and functional avidity as a result of peptide encounter , 2007, Immunology.

[58]  Cheng Zhu,et al.  Kinetics of MHC-CD8 Interaction at the T Cell Membrane1 , 2007, Journal of Immunology.

[59]  L. Stern,et al.  Class II major histocompatibility complex tetramer staining: progress, problems, and prospects , 2008, Immunology.

[60]  T. Schumacher,et al.  MHC multimer technology: current status and future prospects. , 2005, Current opinion in immunology.

[61]  N. Shastri,et al.  Requirement for association of p56 lck with CD4 in antigen-specific signal transduction in T cells , 1991, Cell.

[62]  David M Kranz,et al.  Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. , 2003, Immunity.

[63]  A. Singer,et al.  'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR , 2007, Nature Immunology.

[64]  B. Alarcón,et al.  Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response , 2005, The Journal of experimental medicine.

[65]  J. Frelinger,et al.  Antigen-Specific Modulation of an Immune Response by In Vivo Administration of Soluble MHC Class I Tetramers1 , 2001, The Journal of Immunology.

[66]  J. Altman,et al.  Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. , 1998, Immunity.

[67]  P. Klenerman,et al.  Ultra‐sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells , 2004, European journal of immunology.

[68]  Michael A. Bookman,et al.  The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56 lck , 1988, Cell.

[69]  C. Sharrock T-cell repertoire. , 1988, Immunological Reviews.

[70]  J. Frelinger,et al.  Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. , 2007, Blood.

[71]  C. Leclerc,et al.  In Vivo Induction of a High-Avidity, High-Frequency Cytotoxic T-Lymphocyte Response Is Associated with Antiviral Protective Immunity , 2000, Journal of Virology.

[72]  J. Berzofsky,et al.  Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL , 1996, The Journal of experimental medicine.

[73]  C. Janeway The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. , 1992, Annual review of immunology.

[74]  D. Stuart,et al.  Crystal structure of the complex between human CD8αα and HLA-A2 , 1997, Nature.

[75]  S. Rowland-Jones,et al.  Functional Discrepancies in HIV-Specific CD8+ T-Lymphocyte Populations Are Related to Plasma Virus Load , 2002, Journal of Clinical Immunology.

[76]  Down-regulation of diabetogenic CD 4 + T cells by a soluble dimeric peptide – MHC-class-II chimera , 2002, Nature Reviews Immunology.

[77]  S. Migueles,et al.  Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses , 2005, The Journal of experimental medicine.

[78]  J. Frelinger,et al.  tetramers coupled to the type I ribosome-inactivating protein saporin T cells by MHC class I + Selective deletion of antigen-specific CD8 , 2009 .

[79]  H. Einsele,et al.  Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib , 2008, Clinical Cancer Research.

[80]  R. Phillips,et al.  Antagonism of cytotoxic T lymphocyte‐mediated lysis by natural HIV‐1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides , 1997, European journal of immunology.

[81]  H. Reijonen,et al.  Low‐avidity recognition by CD4+ T cells directed to self‐antigens , 2003, European journal of immunology.

[82]  Jianzhu Chen,et al.  Soluble peptide–MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[84]  A. Trautmann,et al.  CD8 expression allows T cell signaling by monomeric peptide-MHC complexes. , 1998, Immunity.

[85]  J. Bluestone,et al.  Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes1 , 2003, The Journal of Immunology.

[86]  M. Kester,et al.  Investigation of Peptide Involvement in T Cell Allorecognition Using Recombinant HLA Class I Multimers1 , 2005, The Journal of Immunology.

[87]  H. Rammensee,et al.  Cutting Edge: Characterization of Allorestricted and Peptide-Selective Alloreactive T Cells Using HLA-Tetramer Selection1 , 2001, The Journal of Immunology.

[88]  K. Eichmann,et al.  Biochemical evidence of the physical association of the majority of CD3 δ chains with the accessory/co‐receptor molecules CD4 and CD8 on nonactivated T lymphocytes , 1992, European journal of immunology.

[89]  S. Hutchinson,et al.  Recognition of nonpeptide antigens by human Vγ9Vδ2 T cells requires contact with cells of human origin , 2004 .

[90]  A. Sewell,et al.  Coreceptor CD8-driven modulation of T cell antigen receptor specificity. , 2007, Journal of theoretical biology.

[91]  D. Price,et al.  Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry , 2006, Nature Medicine.

[92]  P. A. van der Merwe,et al.  T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand , 2005, Nature.

[93]  Ellis L. Reinherz,et al.  Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[94]  H. Rammensee,et al.  Protective Immunity Does Not Correlate with the Hierarchy of  Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides , 1998, The Journal of experimental medicine.

[95]  A. Sewell,et al.  T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. , 2008, Molecular immunology.

[96]  M. Nishimura,et al.  T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells , 2006, Cancer Immunology, Immunotherapy.

[97]  D. Douek,et al.  Detection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. , 2008, Journal of immunological methods.

[98]  A. Sewell,et al.  CD8 exerts differential effects on the deployment of cytotoxic T lymphocyte effector functions , 2007, European journal of immunology.

[99]  A. Hamad,et al.  Potent T Cell Activation with Dimeric Peptide–Major Histocompatibility Complex Class II Ligand: The Role of CD4 Coreceptor , 1998, The Journal of experimental medicine.

[100]  R. Zamoyska,et al.  Is CD8 dependence a true reflection of TCR affinity for antigen? , 1993, International immunology.

[101]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[102]  E. Jaffee,et al.  Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[103]  S. Casares,et al.  Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide–MHC class II chimera , 2002, Nature Immunology.

[104]  I. Sakita,et al.  In vivo CTL immunity can be elicited by in vitro reconstituted MHC/peptide complex. , 1996, Journal of immunological methods.

[105]  J. Berzofsky,et al.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[106]  J. Frelinger,et al.  Peripheral “CD8 Tuning” Dynamically Modulates the Size and Responsiveness of an Antigen-Specific T Cell Pool In Vivo1 , 2005, The Journal of Immunology.

[107]  T. McKeithan,et al.  Kinetic proofreading in T-cell receptor signal transduction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[108]  D. Legler,et al.  Soluble Major Histocompatibility Complex-Peptide Octamers with Impaired CD8 Binding Selectively Induce Fas-dependent Apoptosis* 210 , 2003, The Journal of Biological Chemistry.

[109]  G. Dolton,et al.  Loss of Src Homology Region 2 Domain-Containing Protein Tyrosine Phosphatase-1 Increases CD8+ T Cell-APC Conjugate Formation and Is Associated with Enhanced In Vivo CTL Function1 , 2007, The Journal of Immunology.

[110]  V. Appay,et al.  A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. , 2001, Immunity.

[111]  B. Walker,et al.  Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.

[112]  A. Sewell,et al.  Different T Cell Receptor Affinity Thresholds and CD8 Coreceptor Dependence Govern Cytotoxic T Lymphocyte Activation and Tetramer Binding Properties* , 2007, Journal of Biological Chemistry.

[113]  S. Jameson,et al.  Critical Role for Cd8 in T Cell Receptor Binding and Activation by Peptide/Major Histocompatibility Complex Multimers , 2000, The Journal of experimental medicine.

[114]  B K Jakobsen,et al.  T cell receptor and coreceptor CD8 alphaalpha bind peptide-MHC independently and with distinct kinetics. , 1999, Immunity.

[115]  VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.

[116]  M. Ostrowski,et al.  Simian Immunodeficiency Virus (SIV) Infection of a Rhesus Macaque Induces SIV-Specific CD8+ T Cells with a Defect in Effector Function That Is Reversible on Extended Interleukin-2 Incubation , 2001, Journal of Virology.

[117]  G. Ogg,et al.  Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. , 1999, Journal of immunology.

[118]  D. Speiser,et al.  Fluorescence-Activated Cell Sorting and Cloning of Bona Fide CD8+ CTL with Reversible MHC-Peptide and Antibody Fab′ Conjugates1 , 2006, The Journal of Immunology.

[119]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.

[120]  P. Marrack,et al.  Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4(+) T cell response to a rheumatoid arthritis-associated antigen. , 2005, Arthritis and rheumatism.

[121]  D. Scheinberg,et al.  Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. , 2004, Blood.

[122]  C. Peota Novel approach. , 2011, Minnesota medicine.

[123]  M. Davis,et al.  Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. , 1999, Journal of immunology.